Americas Orthopedic Biomaterial Market

The prevalence of musculoskeletal disorders and chronic skeletal problems is rising, which is fueling demand for products and accelerating market expansion. The need is anticipated to increase due to the growing senior population, which is more susceptible to these illnesses. For instance, the U.S. Census Bureau reports that from 2014 to 2015, there were 1.6 million more people in the 65 and older age group. Another element driving the increase in demand for orthopedic biomaterials is the increase in trauma cases from falls, accidents, and sports.

The likelihood of injury is rising as more people participate in sport and leisure activities.

Around 213 million Americans aged 6 and older participated in sports and fitness activities in 2015, up from 209 million in 2014, according to National Health Statistics Reports. The expansion of this market is also being aided by an increase in orthopedic procedures including viscosupplementation, joint reconstruction, and joint arthroplasty. Additionally, the need for next-generation orthopedic biomaterials, which are specifically designed to fulfil the requirements of a particular orthopedic operation, is on the rise ly.

On the other side, the market's expansion has been hampered by the restricted payment coverage alternatives for these goods and the falling reimbursement for orthopedic implants in several nations. Additionally, the absence of reimbursements has forced suppliers to reduce the cost of these products, which has slowed the market's expansion.

The ageing of the population, increased incidence of musculoskeletal injuries, and a rise in the number of patients electing knee replacement, joint reconstruction, and other orthopedic surgery involving joints are all expected to have an impact on the market. The World Population Prospects 2022 report from the UN Department of Economic and Social Affairs predicts a rise in the proportion of people 65 and older, from 10% in 2022 to 16% in 2050.

By the year 2050, it's anticipated that the number of persons 65 and older would have surpassed that of children under the age of five and will be nearly equivalent to that of children under the age of twelve. Over the next few years, it is anticipated that the usage of orthopedic biomaterials will increase as the world's ageing population grows more susceptible to joint problems and procedures. According to the July 2022 data from the World Health Organisation, 1.71 billion people worldwide experience musculoskeletal issues.

Due to the rising incidence of musculoskeletal injuries brought on by such a high burden of musculoskeletal illnesses, the market for orthopedic biomaterials is growing. Thus, driving the America Orthopedic Biomaterial Market revenue.

The North America America Orthopedic Biomaterial Market dominated this market in 2022 (45.80%). The increase in patients requiring knee replacement, reconstruction, and other orthopedic surgeries can be attributable to this growth. It is projected that rapid adoption of cutting-edge devices for implant load-bearing and bone gap filling will propel the regional market even further. Further, the U.S. America Orthopedic Biomaterial Market held the largest market share, and the Canada America Orthopedic Biomaterial Market was the fastest growing market in the North America region.

Figure 2 America Orthopedic Biomaterial Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

The market for North American orthopedic biomaterials was dominated by the United States. A considerable portion of the elderly population in the United States is predisposed to musculoskeletal conditions like osteoarthritis and osteoporosis. The demand for orthopedic biomaterials has been driven by the rising occurrence of these illnesses.

In terms of market share for orthopedic biomaterials in North America, Canada came in second. Orthopedic biomaterials are among the areas of healthcare research and development that the Canadian government has been actively pushing. Market expansion has been fueled by funding and programmes meant to foster cutting-edge technologies.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the America Orthopedic Biomaterial Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Orthopedic Biomaterial industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Orthopedic Biomaterial industry to benefit clients and increase the market sector. In recent years, the Orthopedic Biomaterial industry has offered some of the most significant advantages to medicine.

Major players in the America Orthopedic Biomaterial Market, including Materion Corporation, Carpenter Technology Corporation, Ulbrich Stainless Steel & Special Metals, Inc., CeramTec, Ceradyne, Heraeus Medical Components, Kyocera Corporation, Ticona GmbH, Purac Biomaterials, Acumed, Amedica Corporation, Johnson & Johnson, Osteotech, Inc., Cam Bioceramics B.V., and Landec Corporation, are attempting to increase market demand by investing in research and development operations.

Evonik Industries AG (Evonik), a speciality chemical company owned by RAG-Stiftung. Its product range encompasses a wide variety of chemicals, including surfactants, polymers, resins, and additives. The company's products are used in a wide variety of sectors, including agriculture, alternative energy, paints and coatings, paper and printing, metal and oil products, electrical and electronics, food and animal feed, personal care and cosmetics, pharmaceuticals, plastics and rubber, automotive, and construction. Engineering, logistics, utility, and process technology services are also offered. Evonik has significant manufacturing operations in China, Singapore, Belgium, the United States, and Germany.

The company has a footprint that includes not only the Americas but also Asia-Pacific, Africa, South America, and Europe. Evonik's headquarters are located in Essen, Nordrhein-Westfalen, Germany. In March of 2022, Evonik introduced VESTAKEEP Fusion PEEK filament, an osteoconductive material for 3D-printed implants.

A manufacturer of medical devices, Orthofix Medical Inc. (Orthofix), formerly known as Orthofix International NV, offers reconstruction and regenerative musculoskeletal solutions to doctors all over the world. Products for fracture management, regenerative products and tissue forms, paediatrics and limb reconstruction, motion preservation and fixation implant devices, and foot and ankle products are among the company's top offerings. In order to reach hospitals, doctors, integrated health delivery systems, ambulatory surgery centres, and other purchasing organisations worldwide, Orthofix markets its products both directly and through a network of distributors.

In addition to the US, UK, Brazil, Italy, France, and Germany, it also has facilities there. United States-based Orthofix is based in Lewisville, Texas. Opus BA, a blend of carbonate apatite bone mineral, bioactive glass, and Type 1 collagen carrier for cervical and lumbar spine fusion surgeries, was introduced by Orthofix Medical in February 2022.